11C- metomidate positron emission tomography (PET) scanning for Conn's syndrome

Hypertension due to Conn's adenoma - the localisation of adrenal cortical adenomas by 11C-metomidate PET scanning following dexamethasone and fludrocortisone suppression

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN58267591

Enrollment

Registered

2010-05-12

Start date

2009-04-17

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Metabolic and Endocrine

Interventions

In addition to standard investigations for suspected Conn's adenoma, each participant will undergo a positron emission tomography (PET)/computed tomography (CT) scan with intravenous 11C-metomidate (5

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Male or female 2. Aged 18 years or over 3. Suspected Conn's syndrome or suspected adrenal hyperplasia or healthy with non-functional adenoma

Exclusion criteria

Exclusion criteria: 1. Inability to give informed consent 2. Heart failure 3. Women of childbearing potential not using contraception 4. Pregnant or breast feeding women

Design outcomes

Primary

Measure	Time frame
The sensitivity of 11C-metamidate PET/CT scanning for detecting Conn's adenoma	—

Secondary

Measure	Time frame
1. The specificity of 11C-metomidate PET/CT scanning for detecting Conn's Syndrome 2. To determine the suppression protocol that leads to the best sensitivity of 11C-metomidate PET/CT scanning for detecting Conn's Syndrome	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026